Solu Therapeutics
Boston-based Solu Therapeutics develops precision medicine to combat oncologic, inflammatory, and autoimmune diseases.
Founded
2022Boston-based Solu Therapeutics develops precision medicine to combat oncologic, inflammatory, and autoimmune diseases.
Solu Therapeutics, founded by Longwood Fund and based in Boston, Massachusetts, is a precision-medicine company focused on developing therapeutics to eliminate cells that drive oncologic, inflammatory, and autoimmune diseases. The company leverages its proprietary CyTaC (Cytotoxicity Targeting Chimera) platform and drug candidates, licensed from GSK, to target antibody-intractable cell surface markers. Solu Therapeutics aims to revolutionize treatment paradigms in cancer, immunology, and autoimmunity through innovative, targeted therapies.
Notable figures affiliated with Solu Therapeutics include key scientists and industry experts from Longwood Fund and GSK. The company has achieved significant milestones in advancing its CyTaC platform, positioning itself as a leader in precision medicine. By focusing on unmet medical needs and leveraging cutting-edge technology, Solu Therapeutics has made a substantial impact on the therapeutic landscape, offering new hope for patients with challenging diseases.
Companies similar to Solu Therapeutics include Solve Therapeutics, Solarea Bio, Soltego and Soleno Therapeutics.
Solu Therapeutics was founded in 2022.
Solu Therapeutics' headquarters is located in Boston, MA, US.
Solu Therapeutics' most recent funding round was for $31M (USD) in August 2023.
As of Aug 1, 2023, Solu Therapeutics has disclosed funding of $31M (USD). Undisclosed round amounts are excluded.
Solu Therapeutics has 11 employees as of Feb 4, 2024.
Soleno Therapeutics
soleno.life
